Results 51 to 60 of about 29,732,513 (224)

Prevalence of Human T-lymphotropic virus type 1 and 2 among blood donors in Manaus, Amazonas State, Brazil

open access: yesRevista do Instituto de Medicina Tropical de São Paulo, 2017
Introduction: Human T-lymphotropic virus type 1 and 2 (HTLV-1/2) is endemic in Brazil, but few studies have investigated the seroprevalence of HTLV and its subtypes among blood donors in the capital city Manaus, Amazonas State, Brazil.
Márcia Poinho EncarnaçÃo de Morais   +5 more
doaj   +1 more source

HTLV-1 proviral load of symptomatic patients.

open access: yes, 2019
HTLV-1 proviral load of symptomatic patients.
Ariel Fridman (7961834)   +11 more
core   +1 more source

Experiencing 50 Years of Synergistic Development in Structural Biology and Enzymology

open access: yesJournal of the Chinese Chemical Society, EarlyView.
Picture of Sunney Chan with Academia Sinica (AS) President James C. Liao and three Vice Presidents: Shin‐Kun Peng (left one), Tang K. Tang (right one), and Mei‐Yin Chou (right 2), taken at the annual Chinese New Year's Banquet of AS, February 7, 2025. This was likely Sunney's last appearance in formal activities of AS.
Ming‐Daw Tsai
wiley   +1 more source

Epidemiological analysis of HTLV-1 and HTLV-2 infection among different population in Central China. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: HTLV-1 and HTLV-2 are retroviruses linked etiologically to various human diseases, and both of them can be transmitted by vertical route, sexual intercourse, blood transfusion and intravenous drug use.
Yunyun Ma   +9 more
doaj   +1 more source

Is the innate bio-protection power against human virus the same between males and females? A conclusion based on blood donor data of HTLV-I infection [PDF]

open access: yes, 2008
Human T-cell leukemia virus type I (HTLV-I) is a retrovirus that causes adult T-cell leukemia. The male-to-female transmission is stronger than the reverse, so the carrier proportion of women is greater than that of men.
Minoru Tabata   +3 more
core  

Updates on HTLV-1 Uveitis

open access: yesViruses, 2022
HTLV-1 uveitis (HU) is the third clinical entity to be designated as an HTLV-1-associated disease. Although HU is considered to be the second-most frequent HTLV-1-associated disease in Japan, information on HU is limited compared to that on adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy (HAM).
Koju Kamoi   +13 more
openaire   +3 more sources

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

open access: yesImmunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu   +24 more
wiley   +1 more source

Tocilizumab has no direct effect on cell lines infected with human T-cell leukemia virus type 1

open access: yesJournal of International Medical Research, 2021
Objective It remains unclear whether human T-cell leukemia virus type 1 (HTLV-1) infection influences therapeutic responses in patients with rheumatic diseases and whether immunosuppressive treatments increase the risk of HTLV-1-related complications in ...
Yushiro Endo   +9 more
doaj   +1 more source

HTLV-1-associated myelopathy in Spain

open access: yes, 2023
Background HTLV-1 infection is a neglected disease. Over 10 million people are infected worldwide, with hot spots of high endemicity across all continents.
Pozuelo, María José   +12 more
core   +1 more source

Harnessing the Therapeutic Potential of Cell Secretomes and Extracellular Vesicles for Craniofacial Regenerative Applications

open access: yesJournal of Periodontal Research, EarlyView.
The scoping review summarizes the current preclinical and clinical evidence for the use of “cell‐free” therapies in craniofacial (periodontal, bone and soft‐tissue) regeneration. It also aims to highlight key challenges and strategies towards the clinical translation of these therapies.
Siddharth Shanbhag   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy